MyeCare Program Terms and Conditions for Healthcare Professionals

The following terms and conditions (Terms) apply to Healthcare Professionals (HCPs) referring patients to, or receiving information about patient participation in, the MyeCare program (Program) sponsored by GlaxoSmithKline Australia Pty Ltd (GSK) and managed by Partizan Worldwide Pty Ltd (Partizan) (‘us’, ‘we’ or ‘our’).

Please read these Terms and Conditions and the MyeCare Program Privacy Notice. It is your right to refuse to agree to the terms and conditions outlined here; however, if you do not agree, you and your patients may not be able to participate in the MyeCare Program. If you have any questions or require additional information, please contact the MyeCare Program team on 1800 140 272.

Access to, and enrolment of your patient(s) into the MyeCare Program shall constitute acceptance of the following Terms and Conditions:

1. Use of the Program

You may only access and use the Program in accordance with these Terms and other instructions that we may provide you with.

You confirm that you are a Healthcare Professional registered to practice as such in Australia. You acknowledge and agree:

(a) that the Program is a patient support service and does not provide medical advice, treatment guidance or recommendations. You remain independently responsible for any medical management and treatment decisions regarding the care of your patients who are enrolled in the Program;

(b) this Program provides support services identified in section 3 below, and is not intended to influence the recommendation or prescribing of GSK products; and

2. Eligibility and consent

You confirm that your patient is eligible to participate in the Program, on the basis that the patient is being prescribed belantamab mafodotin for relapse or refractory multiple myeloma. If you are unsure, please contact the MyeCare support team for further information. We reserve the right to exclude participants who are not eligible to use the Program. Where you have identified an eligible patient, you must provide the patient with the MyeCare Program Terms and Conditions and the MyeCare Program Privacy Notice and obtain the patient’s informed consent prior to enrolling the patient in the Program. Partizan Worldwide on behalf of GSK may add new presentations of belantamab mafodotin to this Program without notification.

By participating in the MyeCare Program, you consent to the MyeCare Program team corresponding (by phone, email, SMS, mail, websites or digital applications) with you to provide you with information relevant to your referred patient’s status and/or the support services that we have provided to them.

You understand and agree to report Adverse Events involving belantamab mafodotin, in accordance with the booklet titled “Belantamab Mafodotin Managed Access Program: Information on belantamab mafodotin and associated ocular events for prescribers”.

For Adverse Events that have been reported, you understand and agree that Partizan and/or GSK may contact you for further information relating to Adverse Events, if required.

3. Services

Services provided under the Program may vary depending on:

Information provided in the “Your Guide to MyeCare Program booklet”; and
The needs of your patient(s), depending on the GSK product that they have been prescribed.

Services provided under the Program may include:

Patient education on eye test and monitoring requirements provided by a MyeCare Program team member
Help coordinate eye test bookings with a trained optometrist
Summary reports of eye examinations, prepared by the optometrist
Patient reminder services
Patient and HCP access to online information, tools and resources
Patient and HCP access to customer support services provided by the MyeCare Program team

You can refer a patient for enrolment into the MyeCare Program by completing the online patient referral form at myecare.com.au.

We reserve the right to alter or cancel any services under the Program, or the Program itself, at any time.

4. Privacy

Partizan Worldwide will collect, use and store your personal information in accordance with the MyeCare Program Privacy Notice available at www.myecare.com.au/privacy-notice and our obligations under the Privacy Act 1988. We take all reasonable steps to ensure your personal and/or sensitive information is protected from misuse and loss and from unauthorised access, modification or disclosure. If you have any questions, concerns or a complaint regarding the treatment of your privacy, please contact us by phone on 1800 140 272 or by email at support@myecare.com.au.

You consent for your personal information to be collected, used, stored, transferred and disclosed as outlined in the MyeCare Program Privacy Notice, for the purposes of enabling interactions with, and access to, the Program and the Program services, as a treating Healthcare Professional. You also consent for the MyeCare Program team or an authorised trained optometrist to contact you by phone, email, SMS, websites or digital applications or mail for the purposes of facilitating the Program and evaluating the Program for quality improvoordiement purposes.

5. Opt-out

Your registration on the Program system will continue for the duration of the Program or until you opt out. You may opt out at any time by calling 1800 140 272 or writing to the MyeCare Program at support@myecare.com.au.

We may also suspend or cancel your access to the Program at any time without advance notice and for any reason, although we will use reasonable efforts to provide you with notice wherever practicable.

6. Changes to these Terms

We reserve our right to modify these Terms at any time, including Program eligibility requirements. We will use reasonable endeavours to ensure that you are alerted to changes, such as by contacting you via email. Your subsequent continued use of the Program after such changes have been made will constitute acceptance of the new Terms.

We may also update, improve or otherwise modify the software and the Program from time to time.

This Program may be terminated at any time at the direction of GSK, for regulatory or safety reasons or any other reason GSK deems necessary.

7. Contact us

If you have any questions about the Program or these Terms, please contact us by phone on 1800 140 272 or by email at support@myecare.com.au.

For reactive use to a healthcare professional request for compassionate supply of Belantamab mafodotin.

Belantamab mafodotin is not currently approved for use in Australia by the Therapeutic Goods Administration (TGA).

This information is intended for healthcare professionals only. For information on belantamab mafodotin or to report an adverse event involving belantamab mafodotin, please refer to the booklet titled “Belantamab Mafodotin Managed Access Program: Information on belantamab mafodotin and associated ocular events for prescribers”. The MyeCare Program has been developed and supported by GlaxoSmithKline Australia Pty Ltd and is managed by Partizan Worldwide Pty Ltd (an independent provider of patient support services). Partizan Worldwide Pty Ltd, Level 8/321 Kent Street, Sydney NSW 2000. ABN: 18 115 985 825. For information on belantamab mafodotin or to report an adverse event involving belantamab mafodotin, please refer to the booklet titled “Belantamab Mafodotin Managed Access Program: Information on belantamab mafodotin and associated ocular events for prescribers”. GlaxoSmithKline Australia Pty Ltd, ABN 47 100 162 481, Melbourne, VIC. Trade marks are property of their respective owners. ©2025 GSK group of companies or its licensor.

NX-AU-MMU-PSP-250005 Date of Approval: September 2025